HROW Upcoming Earnings (Q3 2023)
|Earnings Date:||Nov 13, 2023|
Current P/E* ratio: -27.46 | Price (Sep 25, 2023, EOD): $14.80
*The P/E ratio (price-to-earnings ratio) is a financial metric used to assess a company's stock valuation. It is calculated by dividing the stock price by its earnings per share. A higher ratio suggests higher investor expectations, while a lower ratio may indicate undervaluation. It helps investors evaluate potential investments, but it's essential to consider other factors too.
Last 3 Quarters for HROW Premium
About Imprimis Pharmaceuticals
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharma... HROW Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.